- Brand Name: Copaxone® (U.S. and Canada) (co-PAX-own)
- Chemical Name: Glatiramer acetate (gla-TEER-a-mer ASS-i-tate) [formerly called Copolymer-1]
- Usage in MS: Disease-Modifying Agent
- Generic Available: Yes
This medication is taken by injection.
Glatiramer acetate is a synthetic protein that simulates myelin basic protein, a component of the myelin that insulates nerve fibers in the brain and spinal cord. This drug seems to block myelin-damaging T-cells through a mechanism that is not completely understood.
Glatiramer acetate is approved by the U.S. Food and Drug Administration (FDA) for relapsing forms of multiple sclerosis, which include clinically isolated syndrome, relapsing-remitting disease (RRMS) and active secondary progressive disease (SPMS with relapses).
In January, 2014, the FDA approved a new 40 mg/mL dose of this medication, injected three times per week, which is double the standard 20 mg/mL dose that is injected daily. The approval was based on benefits and safety demonstrated in a one-year phase III trial comparing the higher, less-frequent dose of the medication with placebo. The standard dosing option continues to be available.
Click here to read the FDA Prescribing Information for healthcare professionals.
To read the Patient Information, go to the FDA Prescribing Information and scroll down to p. 5.
COPAXONE SUPPORT PROGRAM
Financial Assistance Program